BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Korea's medtech firm Ainex Corporation inks deal with Singapore's National University Hospital

August 5, 2026 | News

ENAD secures Singapore Hospital adoption in competition with Medtronic, Olympus, and Fujifilm

South Korea-based Ainex Corporation, a medical AI company specialising in gastrointestinal endoscopy, has signed an agreement with Singapore's National University Hospital (NUH) to supply its real-time AI-assisted diagnostic software for upper and lower gastrointestinal endoscopy, Endoscopy as AI-powered Device (ENAD).

Ainex will also expand its joint clinical research partnership with NUH to further advance ENAD's AI algorithms and enhance its diagnostic performance.

The agreement marks Ainex's full-scale entry into Singapore, one of the world's most competitive medtech markets. Ainex will lead its expansion with ENAD, the only Korean AI-assisted diagnostic solution to have received approval from the Ministry of Food and Drug Safety (MFDS) for both upper and lower gastrointestinal endoscopy.

This milestone, achieved approximately one year after ENAD received regulatory approval from Singapore's Health Sciences Authority (HSA) in April 2025, is particularly significant because it extends beyond a one-off export agreement. The partnership establishes a framework for joint research and development with a world-class medical institution, enabling Ainex and NUH to further enhance ENAD's clinical performance and technological capabilities.

As part of the agreement, NUH has formally adopted ENAD for deployment across all of its endoscopy units. In parallel, Ainex and NUH will expand their joint clinical research to further enhance ENAD's diagnostic performance.

Building on the expanded collaboration, Ainex plans to collect additional real-world data (RWD) to further improve ENAD's diagnostic performance in identifying adenomas and neoplasms, sessile serrated lesions (SSLs) and early gastric cancer (EGC). The company will also accelerate the development and validation of real-time AI algorithms designed to support the assessment of intestinal metaplasia (IM) and inflammatory bowel disease (IBD).